Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Pilot Study of Synchronized and Non-invasive Ventilation ("NeuroPAP") in Preterm Newborns (NeuroPAP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02480205
Recruitment Status : Completed
First Posted : June 24, 2015
Last Update Posted : January 31, 2017
Sponsor:
Collaborator:
Maquet Cardiovascular
Information provided by (Responsible Party):
Dr Guillaume Emeriaud, St. Justine's Hospital

Brief Summary:

There is currently a consensus that non-invasive ventilation (NIV) in preterm infants is preferred over intubation. There are two ways of delivering NIV in preterm infants, nasal continuous positive airway pressure (CPAP) or nasal intermittent positive pressure ventilation (NIPPV), where ventilator inflations are delivered intermittently over a fixed end-expiratory pressure. The synchronization in conventional mode is very difficult to obtain in premature infants. In all ventilation modes PEEP (end-expiratory pressure) is fixed. Considering that preterm infants are more likely to develop atelectasis, an active and ongoing management of the PEEP is very important to prevent de-recruitment.

A new respiratory support system (NeuroPAP) was developed to address these issues (synchronization problems and control the PEEP). It uses the electrical activity of the diaphragm (EDI) to control the ventilator assist continuously, both during inspiration (principle of NAVA mode) and also during expiration (based on tonic Edi level).


Condition or disease Intervention/treatment Phase
Respiratory Failure Device: NeuroBox to deliver the NeuroPAP Not Applicable

Detailed Description:

The mode NeuroPAP will work with the continuous Edi-level and deliver pressures according to the Edi-signal x set NeuroPAP-level, over the whole breath (inspiration and expiration). The NeuroPAP will work between two pressure levels set by the user and named higher Pressure limit (Plimit) and minimum Pressure (Pmin).

A safety upper pressure limit (UPL) will also be set. A backup ventilation will be possible.

A specific gastric tube equipped with an array of microelectrodes (Edi catheter, Maquet, Solna, Sweden) will be installed after inclusion, by the same oral or nasal route as the tube previously in place. Patients will then be ventilated in the 5 aforementioned conditions:

  • On conventional NIPPV device on clinical settings for a 30 minute period. The investigators will note the mean airway pressure being delivered with the clinical settings and the resulting peak Edi, as well as neural respiratory rate, tonic Edi, Fraction of inspired oxygen (FiO2), and Oxygen saturation by pulse oximetry (SpO2).
  • With NeuroPAP without modification of Pmin (=peep). The exchange of the nasal interface may be necessary, depending on the original interface. FiO2 will initially be the same as previously set in conventional NIPPV. The Pmin will initially be set at the level of PEEP used during conventional NIPPV. A titration maneuver will be conducted to identify the optimal NeuroPAP level. The infant will be ventilated for one hour. Clinical adjustments in pressures and FiO2 are permitted. Safety termination will be established.
  • NeuroPAP with adjusted Pmin: the Pmin in NeuroPAP will be reduced by 2 cm H2O, with the same NeuroPAP level. The patients will be ventilated for one hour.
  • CPAP delivery with NeuroPAP device: the device will be switched to CPAP mode, for a 15 minute period
  • A second 30 minutes period of the conventional NIPPV will be conducted.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study of Synchronized and Non-invasive Ventilation ("NeuroPAP") in Preterm Newborns
Study Start Date : August 2015
Actual Primary Completion Date : January 30, 2017
Actual Study Completion Date : January 30, 2017

Arm Intervention/treatment
Experimental: NeuroBox to deliver the NeuroPAP Device: NeuroBox to deliver the NeuroPAP

The patients will be studied during the following conditions:

  • On conventional NIPPV device with the clinically prescribed settings (30 min)
  • With NeuroPAP and no change of Pmin (=peep) (60 min)
  • With NeuroPAP and adjusted Pmin (decreased by 2 cmH2O) (60 min)
  • During CPAP delivered with NeuroPAP device (15 min)
  • Again with original NIPPV device and settings for 30 minutes




Primary Outcome Measures :
  1. Time effectively spent with NeuroPAP mode activated during the NeuroPAP period [ Time Frame: up to 30 minutes after reinstitution of the conventional NIPPV ]
    Percentage

  2. Number of interruption of NeuroPAP during the NeuroPAP period [ Time Frame: up to 30 minutes after reinstitution of the conventional NIPPV ]
    Number of interruption per patients

  3. Change in respiratory rates between standard NIV andNeuroPAP [ Time Frame: up to 30 minutes after reinstitution of the conventional NIPPV ]
    % of change

  4. Change in cardiac rates between standard NIV andNeuroPAP [ Time Frame: up to 30 minutes after reinstitution of the conventional NIPPV ]
    % of change

  5. Change in blood pressure between standard NIV andNeuroPAP [ Time Frame: up to 30 minutes after reinstitution of the conventional NIPPV ]
    % of change

  6. Change in SpO2 between standard NIV andNeuroPAP [ Time Frame: up to 30 minutes after reinstitution of the conventional NIPPV ]
    % of change

  7. Change in TcPCO2 between standard NIV andNeuroPAP [ Time Frame: up to 30 minutes after reinstitution of the conventional NIPPV ]
    % of change


Secondary Outcome Measures :
  1. Time spent in asynchrony between standard NIV and NeuroPAP [ Time Frame: up to 30 minutes after reinstitution of the conventional NIPPV ]
    % of time

  2. Change in trigger delays (ms) between standard NIV andNeuroPAP [ Time Frame: up to 30 minutes after reinstitution of the conventional NIPPV ]
  3. Change in non assisted breaths (wasted efforts) between standard NIV andNeuroPAP [ Time Frame: up to 30 minutes after reinstitution of the conventional NIPPV ]
    % of change

  4. Change in autotriggered breaths between standard NIV and NeuroPAP [ Time Frame: up to 30 minutes after reinstitution of the conventional NIPPV ]
    Percentage

  5. Change in Mean Airway pressure (cmH2O) between standard NIV and NeuroPAP [ Time Frame: up to 30 minutes after reinstitution of the conventional NIPPV ]
  6. Change in End expiratory pressure (PEEP, cmH2O) between standard NIV and NeuroPAP [ Time Frame: up to 30 minutes after reinstitution of the conventional NIPPV ]
  7. Change in Mean Electrical activity of diaphragm (Edi, mcV) between standard NIV and NeuroPAP [ Time Frame: up to 30 minutes after reinstitution of the conventional NIPPV ]
  8. Change in Peak Electrical activity of diaphragm (Edi, mcV) between standard NIV and NeuroPAP [ Time Frame: up to 30 minutes after reinstitution of the conventional NIPPV ]
  9. Change in Tonic Electrical activity of diaphragm (Edi, mcV) between standard NIV and NeuroPAP [ Time Frame: up to 30 minutes after reinstitution of the conventional NIPPV ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 1 Month   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Preterm infants, >26 0/7 and < 34 weeks GA, at least 3 days old and younger than 1 month,
  • on NIPPV with settings in the range : Maximal inspiratory pressure (total, including PEEP) < 20 cmH2O, and PEEP : 5-7 cmH2O,
  • with FiO2 <40%, and stable.

Exclusion Criteria:

  • Suspected or proven pneumothorax
  • Patient on high-flow nasal cannula or nasal continuous positive airway pressure (nCPAP)
  • Infants with severe recurring apnea
  • Recent worsening of respiratory status with increase work of breathing, recent increase in FiO2, or linked with a suspected sepsis
  • Contraindications to the placement of a new nasogastric tube (e.g. severe coagulation disorder, malformation or recent surgery in cervical, nasopharyngeal or esophageal regions)
  • Hemodynamic instability requiring inotropes.
  • Severe respiratory instability requiring imminent intubation according to the attending physician, or FiO2 > 45%, or PaCO2 > 65 mmHg on blood gas in the last hour.
  • Patient for whom a limitation of life support treatments is discussed or decided.
  • Refusal by the treating physician.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02480205


Locations
Layout table for location information
Canada, Quebec
St. Justine's Hospital
Montreal, Quebec, Canada, H3T 1C5
Sponsors and Collaborators
St. Justine's Hospital
Maquet Cardiovascular
Investigators
Layout table for investigator information
Principal Investigator: Guillaume Emeriaud, MD, PhD St. Justine's Hospital
Principal Investigator: Gregory Lodygensky, MD, PhD St. Justine's Hospital
Principal Investigator: Jennifer Beck, PhD Li Ka Shing Knowledge Institute. St. Michael's Hospital
Principal Investigator: Christer Sinderby, PhD Li Ka Shing Knowledge Institute. St. Michael's Hospital
Layout table for additonal information
Responsible Party: Dr Guillaume Emeriaud, MD, PhD, St. Justine's Hospital
ClinicalTrials.gov Identifier: NCT02480205    
Other Study ID Numbers: CHUSJ-4083
First Posted: June 24, 2015    Key Record Dates
Last Update Posted: January 31, 2017
Last Verified: January 2017
Keywords provided by Dr Guillaume Emeriaud, St. Justine's Hospital:
CPAP
NIV
NIPPV
Edi
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Insufficiency
Respiration Disorders
Respiratory Tract Diseases